A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
This is a study with two sequential cohorts, each with three treatment periods. Single doses
 of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose
 projected to be under the current limits for drug concentration. Each cohort will aim to
 achieve approximately 9 completers. Primary endpoint is safety and tolerability, secondary
 endpoint is MDS-UPDRS part III.
Inclusion Criteria:

 -  L-DOPA-responsiveness

 -  Hoehn & Yahr Stage II-III inclusive

 -  Experiencing motor fluctuations

 -  Stable daily dose of L-DOPA of at least 300 mg

 -  Females on non-childbearing potential and male subjects

 Exclusion Criteria:

 -  History of troublesome dyskinesias

 -  History of surgical intervention for Parkinson's disease